Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2209783 | 1.00 | ADRB2 (0.59) | ADRB2SMYD2 | |
| Bromide SCHEMBL1682997 | 0.99 | ADRB2 (0.59) | ADRB2SMYD2 | |
| SCHEMBL2212570 | 0.99 | ADRB2 (0.60) | ADRB2SMYD2 | |
| Sulfuric Acid SCHEMBL3044295 | 0.97 | ADRB2 (0.57) | ADRB2SMYD2 | |
| SCHEMBL1683019 | 0.96 | ADRB2 (0.58) | ADRB2SMYD2 | |
| SCHEMBL1683056 | 0.93 | ADRB2 (0.53) | ADRB2SMYD2 | |
| SCHEMBL1683045 | 0.93 | ADRB2 (0.53) | ADRB2SMYD2 | |
| SCHEMBL2210692 | 0.93 | SMYD2 (0.52) | ADRB2SMYD2 | |
| SCHEMBL2213469 | 0.93 | SMYD2 (0.52) | ADRB2SMYD2 | |
| SCHEMBL2212701 | 0.92 | SMYD2 (0.55) | ADRB2SMYD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2448623-B1 | DISPENSER AND METHOD FOR ENTRAINING POWDER IN AN AIRFLOW | ASTRAZENECA AB (SE) | 2017-12-20 | — | — | EP | claimed |
| EP-2341968-B1 | A BREATH ACTIVATED INHALER | ASTRAZENECA AB (SE) | 2017-05-10 | — | — | EP | claimed |
| US-9289565-B2 | Inhaler with indexing linked to movement of cover | ASTRAZENECA AB (SE) | 2016-03-22 | — | — | US | claimed |
| EP-2334358-B1 | INHALATION DEVICE FOR DISPENSING MEDICAMENT | ASTRAZENECA AB (SE) | 2016-02-10 | — | — | EP | claimed |
| US-9155851-B2 | Breath activated inhaler | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | claimed |
| US-9095670-B2 | Inhalation device and method of dispensing medicament | ASTRAZENECA AB (SE) | 2015-08-04 | — | — | US | claimed |
| EP-2595683-B1 | Inhaler | ASTRAZENECA AB (SE) | 2015-03-04 | — | — | EP | claimed |
| CN-102245238-B | Breath actuated inhaler | ASTRAZENECA AB | 2014-09-10 | — | — | CN | claimed |
| US-20140083422-A1 | INHALER | ASTRAZENECA AB | 2014-03-27 | — | — | US | claimed |
| US-8578933-B2 | Entraining powder in an airflow | ASTRAZENECA AB (SE) | 2013-11-12 | — | — | US | claimed |
| WO-2011061527-A1 | COMBINATIONS COMPRISING A GLUCOCORTICOID RECEPTOR MODULATOR FOR THE TREATMENT OF RESPIRATORY DISEASES | ASTRAZENECA AB (SE) | 2011-05-26 | — | — | WO | claimed |
| EP-2303266-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| US-20100261690-A1 | NOVEL COMBINATIONS | ASTRAZENECA R&D (SE) | 2010-10-14 | — | — | US | claimed |
| US-20100249200-A1 | Novel Compounds 569 | ASTRAZENECA AB (SE) | 2010-09-30 | — | — | US | claimed |
| US-20100144606-A1 | COMBINATION 408 | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | claimed |
| US-7700782-B2 | Compounds 569 | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | claimed |
| WO-2010042033-A1 | INHALATION DEVICE AND METHOD OF DISPENSING MEDICAMENT | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | WO | claimed |
| WO-2010042034-A1 | A BREATH ACTIVATED INHALER | ASTRAZENECA AB (SE) | 2010-04-15 | — | — | WO | claimed |
| US-20100051027-A1 | Entraining Powder In An Airflow | ASTRAZENECA AB (SE) | 2010-03-04 | — | — | US | claimed |
| WO-2009154562-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A 4-HYDROXY-2-OXO-2, 3- DIHYDRO-1, 3-BENZOTHIAZOL-7-YL COMPOUND FOR MODULATION OF BETA2-ADRENORECEPTOR ACTIVITY | ASTRAZENECA AB (SE) | 2009-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261690-A1 | NOVEL COMBINATIONS | ADRB2, NR3C2, GRK4 | ADRB2 1/4885SMYD2 2137/4885 |
| US-20100144606-A1 | COMBINATION 408 | NR3C2, PTGER2, LTB4R2 | ADRB2 51/4885SMYD2 2482/4885 |
| US-20100249200-A1 | Novel Compounds 569 | RB1, CNKSR1, CDK9 | ADRB2 1549/4885SMYD2 3840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.